Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Equity Average (2016 - 2025)

Historic Equity Average for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $1.8 million.

  • Lifecore Biomedical, Inc. \De\'s Equity Average fell 8770.73% to $1.8 million in Q2 2025 from the same period last year, while for May 2025 it was $1.8 million, marking a year-over-year decrease of 8770.73%. This contributed to the annual value of $6.3 million for FY2025, which is 7856.03% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Equity Average stood at $1.8 million for Q2 2025, which was down 8770.73% from $8.8 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Equity Average registered a high of $205.1 million during Q1 2021, and its lowest value of -$8.9 million during Q3 2023.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Equity Average had a median value of $34.2 million in 2023 and averaged $72.1 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Equity Average plummeted by 11073.64% in 2023, and later soared by 19482.66% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Equity Average stood at $174.3 million in 2021, then crashed by 57.25% to $74.5 million in 2022, then crashed by 108.15% to -$6.1 million in 2023, then surged by 194.83% to $5.8 million in 2024, then plummeted by 69.03% to $1.8 million in 2025.
  • Its Equity Average was $1.8 million in Q2 2025, compared to $8.8 million in Q1 2025 and $5.8 million in Q4 2024.